Clinical significance of Mena and Her-2 expression in breast cancer

European Journal of Gynaecological Oncology

Volumn 33, Issue 5, 2012, Pages 455-458

  Du, J W ^a   Xu, K Y ^a   Fang, L Y ^a   Qi, X L ^a  

^a ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Breast cancer; Clinicopathological parameter; Her 2; Immunohistochemistry; Mena

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MENA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICROFILAMENT PROTEINS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 84868609464     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Botha J.L., Bray F., Sankila R., Parkin D.M.: "Breast cancer incidence and mortality trends in 16 European countries". Eur. J. Cancer, 2003, 39, 1718.
2. DeSantis C., Siegel R., Bandi P., Jemal A.: "Breast cancer statistics, 2011". CA Cancer J. Clin., 2011, 61, 409.
3. Long N., Moore M.A., Chen W., Gao C.M., Lai M.S., Mizoue T. et al.: "Cancer epidemiology and control in north-East Asia - past, present and future". Asian Pac J. Cancer Prev., 2010, 11 (suppl. 2), 107.
4. Mazurek M.S.: "Sedation and analgesia for procedures outside the operating room". Semin. Pediatr. Surg., 2004, 13, 166.
5. Mao J., Hai J., Shu H.P., Wu Y.H., Ou H.Y., Luo S.Y. et al.: "Expressions of survivin and nm23 and the relationship among the expressions and the axillary lymph node metastasis in breast cancer". Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2005, 30, 312.
6. Liu B.B., Wei J., Fu L.: "Updates on genes related to breast cancer metastasis". Zhonghua Bing Li Xue Za Zhi, 2008, 37, 266.
7. Kwiatkowski A.V., Gertler F.B., Loureiro J.J.: "Function and regulation of Ena/VASP proteins". Trends Cell. Biol., 2003, 13, 386.
8. Hoffman L.M., Jensen C., Kloeker S., Wang C.L., Yoshigi M., Beckerle M.C.: "Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility, and deficits in actin remodeling". J. Cell Bio., 2006, 172, 771.
9. Di Modugno F., Mottolese M., Di Benedetto A., Conidi A., Novelli F., Perracchio L. et al.: "The cytoskeleton regulatory protein hMena ENAH is overexpressed in human benign breast lesions with high risk of transformation and human epiderma growth factor receptor 2 positive hormonal receptor negative tumors". Clin. Cancer Res., 2006, 12, 1470.
10. Milier J.K., Shattuck D.L., Ingalla E.Q., Yen L., Bowowsky A.D., Young L.J. el al.: "Suppression of the negative regulator contributes to ErbB2 overexpression in breast cancer". Cancer Res., 2008, 68, 8286.
11. Browne B.C., O'Brien N., Dufly M.J., Crown J., O Donovan N.: "HER-2 signaling and inhibition in breast cancer". Curr. Drug. Targets, 2009, 9, 419.
12. Philippar U., Roussos E.T., Oser M., Yamaguchi H., Kim H.D., Giampieri S. et al.: "A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis". Dev. Cell., 2008, 15, 813.
13. Xu Z.H., Ford B.D.: "Upregulation of erbB receptors in rat brain after middle cerebral arteria occlusion". Neurosei Lett., 2005, 375, 181.
14. Wang Y.J., Wang N., Wang B., Qin W.X., Xue C.Y.: "Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer". Zhonghua Zhong Liu Za Zhi, 2009, 31, 346.
15. Spector N.L., Blackwell K.L.: "Understanding the mechanism behind trastuzumab therapy for human epidermal growth factor receptor2 positive breast cancer". J. Clin. Oncol., 2009, 27, 5838.
16. Kröger N., Milde-Langosch K., Riethdorf S., Schmoor C., Schumacher M., Zander A.R. et al:. "Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients". Clin. Cancer Res., 2006, 12, 159.